Business

Reckitt Benckiser: Know the Business

Reckitt is a portfolio in transition: two world-class branded businesses — Hygiene and Health — generating roughly £10bn in revenue at around 26% EBITDA margins in normal years, attached to a structurally impaired infant formula division (IFCN) that has destroyed over £6bn in goodwill since its ill-fated $16.6bn acquisition in 2017. The market prices the whole at approximately 7.5x EV/adj EBITDA, roughly half the peer average, penalising the core franchise for sins committed by a single acquisition. With Essential Home already divested (December 2025) and IFCN under active sale process, portfolio cleanup is removing the discount faster than most models have captured.

1. How This Business Actually Works

Reckitt earns outsized returns through brand monopolies in daily-necessity categories — the economics of defending a shelf position are far cheaper than the economics of attacking one.

Think of it as a toll road. Dettol, Nurofen, and Mucinex are not interchangeable commodities; they are category defaults. When a UK household reaches for an antiseptic, Dettol gets the benefit of the doubt automatically. That defaults-to-brand behaviour drives roughly 59% gross margins and justifies the ~24% of revenue spent on marketing and distribution to maintain it.

The economic model has four layers: brand premium creates pricing power → pricing power sustains gross margins above 58% → fixed-cost leverage on R&D and shared services drives EBITDA margins to 23-27% → asset-light manufacturing (capex under 4% of revenue) converts most EBITDA to cash. The bottleneck is not supply chain or manufacturing; it is brand equity, earned over decades and defensible through category innovation and regulatory positioning (OTC licensing, NHS formulary listings, hospital channel relationships).

Hygiene and Health together represent ~76% of FY2024 revenue and have been broadly stable. IFCN — down from £3.6bn to £3.2bn year on year — runs below group-average margins and dilutes the reported blended result. The strategic logic for divesting it is straightforward.

2. The Playing Field

Reckitt's core Hygiene + Health franchise has margins comparable to Haleon and Colgate, but trades at barely half their valuation multiples — the entire gap is IFCN and litigation, not brand quality.

Reckitt is the clear outlier: EBITDA margins nearly identical to Haleon (22.5-23%), but valued at 7.5x versus Haleon's 13.5x. Haleon is the right comparable — it was spun out of GSK's consumer health business and sits at the same intersection of OTC health brands and defensive demand characteristics. An IFCN disposal that cleans up the balance sheet and litigation exposure is the direct path from 7.5x to 11-13x.

3. Is This Business Cyclical?

Reckitt's core Hygiene and Health divisions behave like utilities in downturns — FCF has sat within a £400M range (£1.8-2.3bn) for five consecutive years across a pandemic surge, inflationary shock, and a major operational disruption at IFCN.

The business does not respond to GDP in a conventional sense. Instead it has two distinct non-macro exposures:

The COVID pull-forward (FY2020): Dettol and Lysol demand surged as consumers stockpiled. Revenue hit £14.0bn — the highest in the company's history at that time — then contracted £757m as demand normalised in FY2021. This was a category event, not a business-model test.

The IFCN structural decline (FY2023-present): US birth rates have declined, the China IFCN operation was sold in 2021, market share has been lost to Abbott's Similac, and NEC litigation has damaged brand trust in the hospital channel. This is secular, not cyclical.

The margin compression from 26.7% (FY2022) to 23.3% (FY2024) is almost entirely IFCN-driven — a £3.2bn segment running below group-average margins on declining revenues. It does not reflect deterioration in the Hygiene or Health brands. The FCF line barely moves because the core cash engine is Hygiene + Health, not IFCN.

4. The Metrics That Actually Matter

Five metrics explain the vast majority of value creation and failure at Reckitt. Reported net income and reported P/E explain almost none of it.

Why these five — and not the conventional ones:

1. Adj EBITDA margin is the cleanest signal of brand health and pricing power. Reported net income is useless at Reckitt given recurring non-cash impairments. EBITDA margin tells you whether brands are generating economic surplus. Target: above 23% near-term, recovering toward 25-27% post-IFCN disposal.

2. FCF margin has ranged 13.9-15.7% of revenue across five years regardless of the macro environment. This stability is exceptional and underpriced. Revenue might fluctuate; cash generation barely does.

3. FCF conversion (FCF / adj net income) at 89% tells you earnings are real. The gap between adjusted earnings and cash is small, confirming low capex intensity and good working capital management. Numbers below 75% in FMCG companies are a warning sign; Reckitt's 80-89% range is consistent and credible.

4. Net debt / adj EBITDA spiked from 1.4x to 1.9x in FY2024 — not because debt increased, but because adj EBITDA fell (IFCN drag). The underlying debt load is manageable. IFCN sale proceeds would mechanically reduce this below 1.0x, freeing material buyback capacity.

5. Core Reckitt LFL net revenue growth is the only metric that proves whether the brands are growing or just being re-priced. FY2024: Hygiene +1.2%, Health +2.8%. Management medium-term guidance post-divestiture: 4-5% LFL. Missing this consistently would be the signal that the moat is weaker than assumed.

5. What I'd Tell a Young Analyst

The business underneath the noise is genuinely excellent. The stock is cheap for real reasons. The thesis requires monitoring two specific things — everything else is noise.

The easy error: look at the £1.1bn GAAP net loss in FY2024 and conclude the business is broken. It is not. Every penny of that loss is non-cash goodwill impairment on a single acquisition made nine years ago. The underlying machine generated £2.1bn in free cash flow in the same year. The GAAP P&L is actively misleading.

The harder insight: Reckitt is not primarily mispriced because of earnings confusion. It is mispriced because of NEC litigation uncertainty. The first verdict ($60m, March 2024) was overturned on procedural grounds (March 2025), but new bellwether trials are expected throughout 2026. If scientific consensus moves against Reckitt — the jury is genuinely out on whether cow's milk preterm formula causes necrotising enterocolitis — the total liability across thousands of filed cases could become the dominant variable in the thesis. The comparable Abbott verdicts total over $500m. The Reckitt exposure may be similar in scale.

Watch these two things:

1. NEC litigation trajectory. Not individual verdicts — those are too noisy — but the settlement trajectory and whether Reckitt is able to ring-fence NEC liability through an IFCN sale that includes a clean indemnity structure. A sale with proper liability transfer is worth significantly more to Reckitt than a sale without one. That distinction — not the price of the IFCN business — is the most important structural question in the investment case right now.

2. Health division LFL growth. Nurofen, Gaviscon, and Mucinex are the highest-margin, most moat-protected assets in the portfolio, operating with OTC regulatory barriers that competitors cannot quickly replicate. Consistent Health LFL above 3% proves the moat is intact. A sustained miss in Health — particularly US Mucinex — would indicate a genuine brand problem rather than an accounting one.

The market may be overestimating NEC litigation risk (anchoring on large Abbott verdicts with somewhat different legal facts) while underestimating the pace of portfolio cleanup. The £2bn annual FCF floor is the margin of safety. At current prices, you collect a 7.3% dividend yield — recently raised 5% to 212.2p for FY2025 — while the portfolio restructuring plays out.